These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8324301)

  • 1. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.
    Holliday SM; Plosker GL
    Drugs Aging; 1993; 3(3):278-99. PubMed ID: 8324301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor.
    Nemeroff CB
    Pharmacotherapy; 1994; 14(2):127-38. PubMed ID: 8197030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Dechant KL; Clissold SP
    Drugs; 1991 Feb; 41(2):225-53. PubMed ID: 1709852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.
    Haria M; Fitton A; McTavish D
    Drugs Aging; 1994 Apr; 4(4):331-55. PubMed ID: 8019056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine: an update of its use in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    Drugs; 2002; 62(4):655-703. PubMed ID: 11893234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine. A pharmacoeconomic evaluation of its use in depression.
    Wilde MI; Whittington R
    Pharmacoeconomics; 1995 Jul; 8(1):62-81. PubMed ID: 10155603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirtazapine: a review of its use in major depression.
    Holm KJ; Markham A
    Drugs; 1999 Apr; 57(4):607-31. PubMed ID: 10235695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical effects of serotonin reuptake inhibitors--a review].
    Feighner JP
    Fortschr Neurol Psychiatr; 1994 Sep; 62 Suppl 1():9-15. PubMed ID: 7959528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tianeptine: a review of its use in depressive disorders.
    Wagstaff AJ; Ormrod D; Spencer CM
    CNS Drugs; 2001; 15(3):231-59. PubMed ID: 11463130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxetine: an overview of dosage, tolerability, and safety.
    Jenner PN
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():69-80. PubMed ID: 1431015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.
    Davis R; Whittington R; Bryson HM
    Drugs; 1997 Apr; 53(4):608-36. PubMed ID: 9098663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression.
    Nemeroff CB
    J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):10S-17S. PubMed ID: 8106649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A risk-benefit assessment of mirtazapine in the treatment of depression.
    Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
    Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.
    Wilde MI; Plosker GL; Benfield P
    Drugs; 1993 Nov; 46(5):895-924. PubMed ID: 7507038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study.
    Bird H; Broggini M
    J Rheumatol; 2000 Dec; 27(12):2791-7. PubMed ID: 11128665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Milne RJ; Goa KL
    Drugs; 1991 Mar; 41(3):450-77. PubMed ID: 1711447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venlafaxine. A review of its pharmacology and therapeutic potential in depression.
    Holliday SM; Benfield P
    Drugs; 1995 Feb; 49(2):280-94. PubMed ID: 7729333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness.
    Harris MG; Benfield P
    Drugs Aging; 1995 Jan; 6(1):64-84. PubMed ID: 7696780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients.
    Geretsegger C; Stuppaeck CH; Mair M; Platz T; Fartacek R; Heim M
    Psychopharmacology (Berl); 1995 Jun; 119(3):277-81. PubMed ID: 7675961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.